The DOI matches its Crossref record; 48 of the 48 references it cites were found in a registry or an index.
Immune-related adverse events for anti-PD-1 and anti-PD-L1 drugs: systematic review and meta-analysis
Open accessAbstract
OBJECTIVE: To evaluate rates of serious organ specific immune-related adverse events, general adverse events related to immune activation, and adverse events consistent with musculoskeletal problems for anti-programmed cell death 1 (PD-1) drugs overall and compared with control treatments. DESIGN: Systematic review and meta-analysis. DATA SOURCES: Medline, Embase, Cochrane Library, Web of Science, and Scopus searched to 16 March 2017 and combined with data from ClinicalTrials.gov. STUDY SELECTION: Eligible studies included primary clinical trial data on patients with cancer with recurrent or metastatic disease. DATA EXTRACTION: Three independent investigators extracted data on adverse events from ClinicalTrials.gov and the published studies. Risk of bias was assessed using the Cochrane tool by three independent investigators. RESULTS: 13 relevant studies were included; adverse event data were available on ClinicalTrials.gov for eight. Studies compared nivolumab (n=6), pembrolizumab (5), or atezolizumab (2) with chemotherapy (11), targeted drugs (1), or both (1). Serious organ specific immune-related adverse events were rare, but compared with standard treatment, rates of hypothyroidism (odds ratio 7.56, 95% confidence interval 4.53 to 12.61), pneumonitis (5.37, 2.73 to 10.56), colitis (2.88, 1.30 to 6.37), and hypophysitis (3.38, 1.02 to 11.08) were increased with anti-PD-1 drugs. Of the general adverse events related to immune activation, only the rate of rash (2.34, 2.73 to 10.56) increased. Incidence of fatigue (32%) and diarrhea (19%) were high but similar to control. Reporting of adverse events consistent with musculoskeletal problems was inconsistent; rates varied but were over 20% in some studies for arthraligia and back pain. CONCLUSIONS: Organ specific immune-related adverse events are uncommon with anti-PD-1 drugs but the risk is increased compared with control treatments. General adverse events related to immune activation are largely similar. Adverse events consistent with musculoskeletal problems are inconsistently reported but adverse events may be common.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Preferred Reporting Items for Systematic Reviews and Meta-Analyses: the PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & for the PRISMA Group (2009) · BMJ · doi:10.1136/bmj.b2535 · Cited by 83,823
Preferred reporting items for systematic reviews and meta-analyses: The PRISMA statement
Moher, D., Liberati, A., Tetzlaff, J., Altman, D. G., & the PRISMA Group* (2009) · Annals of Internal Medicine · doi:10.7326/0003-4819-151-4-200908180-00135 · Cited by 37,554
The Cochrane Collaboration's tool for assessing risk of bias in randomised trials
Higgins, J. P. T., Altman, D. G., Gotzsche, P. C., Juni, P., Moher, D., Oxman, A. D., Savovic, J., Schulz, K. F., Weeks, L., Sterne, J. A. C., et al. (2011) · BMJ · doi:10.1136/bmj.d5928 · Cited by 33,817
PD-1 and PD-L1 Immune Checkpoint Blockade to Treat Breast Cancer
Hartkopf, A. D., Taran, F.-A., Wallwiener, M., Walter, C. B., Krämer, B., Grischke, E.-M., & Brucker, S. Y. (2016) · Breast Care · doi:10.1159/000453569 · Cited by 30,845
Dermyshi, E., Wang, Y., Yan, C., Hong, W., Qiu, G., Gong, X., & Zhang, T. (2017) · Neonatology · doi:10.1159/000454668 · Cited by 24,451
Adverse Renal Effects of Immune Checkpoint Inhibitors: A Narrative Review
Wanchoo, R., Karam, S., Uppal, N. N., Barta, V. S., Deray, G., Devoe, C., Launay-Vacher, V., Jhaveri, K. D., & on behalf of Cancer and Kidney International Network Workgroup on Immune Checkpoint Inhibitors (2017) · American Journal of Nephrology · doi:10.1159/000455014 · Cited by 15,256
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Reck, M., Rodríguez-Abreu, D., Robinson, A. G., Hui, R., Csőszi, T., Fülöp, A., Gottfried, M., Peled, N., Tafreshi, A., Cuffe, S., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1606774 · Cited by 10,089
Nivolumab versus docetaxel in advanced nonsquamous non-small-cell lung cancer
Borghaei, H., Paz-Ares, L., Horn, L., Spigel, D. R., Steins, M., Ready, N. E., Chow, L. Q., Vokes, E. E., Felip, E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1507643 · Cited by 9,335
Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer
Brahmer, J., Reckamp, K. L., Baas, P., Crinò, L., Eberhardt, W. E. E., Poddubskaya, E., Antonia, S., Pluzanski, A., Vokes, E. E., Holgado, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1504627 · Cited by 8,447
Herbst, R. S., Baas, P., Kim, D.-W., Felip, E., Pérez-Gracia, J. L., Han, J.-Y., Molina, J., Kim, J.-H., Arvis, C. D., Ahn, M.-J., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(15)01281-7 · Cited by 6,449
Nivolumab versus Everolimus in Advanced Renal-Cell Carcinoma
Motzer, R. J., Escudier, B., McDermott, D. F., George, S., Hammers, H. J., Srinivas, S., Tykodi, S. S., Sosman, J. A., Procopio, G., Plimack, E. R., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1510665 · Cited by 5,807
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., Dutriaux, C., Maio, M., Mortier, L., Hassel, J. C., Rutkowski, P., McNeil, C., Kalinka-Warzocha, E., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1412082 · Cited by 5,519
Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck
Ferris, R. L., Blumenschein, G., Fayette, J., Guigay, J., Colevas, A. D., Licitra, L., Harrington, K., Kasper, S., Vokes, E. E., Even, C., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1602252 · Cited by 5,101
Rittmeyer, A., Barlesi, F., Waterkamp, D., Park, K., Ciardiello, F., von Pawel, J., Gadgeel, S. M., Hida, T., Kowalski, D. M., Dols, M. C., et al. (2017) · The Lancet · doi:10.1016/s0140-6736(16)32517-x · Cited by 4,675
Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma
Bellmunt, J., de Wit, R., Vaughn, D. J., Fradet, Y., Lee, J.-L., Fong, L., Vogelzang, N. J., Climent, M. A., Petrylak, D. P., Choueiri, T. K., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1613683 · Cited by 3,395
Fehrenbacher, L., Spira, A., Ballinger, M., Kowanetz, M., Vansteenkiste, J., Mazieres, J., Park, K., Smith, D., Artal-Cortes, A., Lewanski, C., et al. (2016) · The Lancet · doi:10.1016/s0140-6736(16)00587-0 · Cited by 2,756
Weber, J. S., D'Angelo, S. P., Minor, D., Hodi, F. S., Gutzmer, R., Neyns, B., Hoeller, C., Khushalani, N. I., Miller, W. H., Lao, C. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)70076-8 · Cited by 2,676
Self-citationFulminant Myocarditis with Combination Immune Checkpoint Blockade
Johnson, D. B., Balko, J. M., Compton, M. L., Chalkias, S., Gorham, J., Xu, Y., Hicks, M., Puzanov, I., Alexander, M. R., Bloomer, T. L., et al. (2016) · New England Journal of Medicine · doi:10.1056/nejmoa1609214 · Cited by 2,308
De-duplication of database search results for systematic reviews in EndNote
Bramer, W. M., Giustini, D., de Jonge, G. B., Holland, L., & Bekhuis, T. (2016) · Journal of the Medical Library Association : JMLA · doi:10.3163/1536-5050.104.3.014 · Cited by 2,103 · cited 1×
“12”
Ribas, A., Puzanov, I., Dummer, R., Schadendorf, D., Hamid, O., Robert, C., Hodi, F. S., Schachter, J., Pavlick, A. C., Lewis, K. D., et al. (2015) · The Lancet Oncology · doi:10.1016/s1470-2045(15)00083-2 · Cited by 1,572
Langer, C. J., Gadgeel, S. M., Borghaei, H., Papadimitrakopoulou, V. A., Patnaik, A., Powell, S. F., Gentzler, R. D., Martins, R. G., Stevenson, J. P., Jalal, S. I., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30498-3 · Cited by 1,404
Ritchlin, C. T., Colbert, R. A., & Gladman, D. D. (2017) · New England Journal of Medicine · doi:10.1056/nejmra1505557 · Cited by 1,404
Toxicities of Immunotherapy for the Practitioner
Weber, J. S., Yang, J. C., Atkins, M. B., & Disis, M. L. (2015) · Journal of Clinical Oncology · doi:10.1200/jco.2014.60.0379 · Cited by 650
IMS Institute for Healthcare Informatics
Evans, R. (2014) · Nursing Standard · doi:10.7748/ns2014.04.28.32.30.s36 · Cited by 594
Neurological, respiratory, musculoskeletal, cardiac and ocular side-effects of anti-PD-1 therapy
Zimmer, L., Goldinger, S. M., Hofmann, L., Loquai, C., Ugurel, S., Thomas, I., Schmidgen, M. I., Gutzmer, R., Utikal, J. S., Göppner, D., et al. (2016) · European Journal of Cancer · doi:10.1016/j.ejca.2016.02.024 · Cited by 562
Nivolumab in Previously Untreated Melanoma without BRAF Mutation
Robert, C., Long, G. V., Brady, B., et al. (2015) · Kölner Universitäts PublikationsServer (Universität zu Köln) · Cited by 495
De Velasco, G., Je, Y., Bossé, D., Awad, M. M., Ott, P. A., Moreira, R. B., Schutz, F., Bellmunt, J., Sonpavde, G. P., Hodi, F. S., et al. (2017) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-16-0237 · Cited by 486
Abdel-Wahab, N., Shah, M., & Suarez-Almazor, M. E. (2016) · PLOS ONE · doi:10.1371/journal.pone.0160221 · Cited by 444
Key Concepts of Clinical Trials: A Narrative Review
Umscheid, C. A., Margolis, D. J., & Grossman, C. E. (2011) · Postgraduate Medicine · doi:10.3810/pgm.2011.09.2475 · Cited by 410
Cappelli, L. C., Gutierrez, A. K., Bingham, C. O., & Shah, A. A. (2017) · Arthritis Care & Research · doi:10.1002/acr.23177 · Cited by 403
Inflammatory arthritis and sicca syndrome induced by nivolumab and ipilimumab
Cappelli, L. C., Gutierrez, A. K., Baer, A. N., Albayda, J., Manno, R. L., Haque, U., Lipson, E. J., Bleich, K. B., Shah, A. A., Naidoo, J., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2016-209595 · Cited by 400
Läubli, H., Balmelli, C., Bossard, M., Pfister, O., Glatz, K., & Zippelius, A. (2015) · Journal for ImmunoTherapy of Cancer · doi:10.1186/s40425-015-0057-1 · Cited by 319
Kostine, M., Rouxel, L., Barnetche, T., Veillon, R., Martin, F., Dutriaux, C., Dousset, L., Pham-Ledard, A., Prey, S., Beylot-Barry, M., et al. (2018) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-212257 · Cited by 306
Larkin, J., Chmielowski, B., Lao, C. D., Hodi, F. S., Sharfman, W., Weber, J., Suijkerbuijk, K. P. M., Azevedo, S., Li, H., Reshef, D., et al. (2017) · The Oncologist · doi:10.1634/theoncologist.2016-0487 · Cited by 267
Belkhir, R., Burel, S. L., Dunogeant, L., Marabelle, A., Hollebecque, A., Besse, B., Leary, A., Voisin, A.-L., Pontoizeau, C., Coutte, L., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-211216 · Cited by 242
Management of Adverse Events Following Treatment With Anti-Programmed Death-1 Agents
Weber, J. S., Postow, M., Lao, C. D., & Schadendorf, D. (2016) · The Oncologist · doi:10.1634/theoncologist.2016-0055 · Cited by 237
Saini, P., Loke, Y. K., Gamble, C., Altman, D. G., Williamson, P. R., & Kirkham, J. J. (2014) · BMJ · doi:10.1136/bmj.g6501 · Cited by 209
Anvik, T., Holtedahl, K. A., & Mikalsen, H. (2006) · BMC Family Practice · doi:10.1186/1471-2296-7-19 · Cited by 143
Risk of pneumonitis in cancer patients treated with immune checkpoint inhibitors: a meta-analysis
Abdel-Rahman, O. M., & Fouad, M. (2016) · Therapeutic Advances in Respiratory Disease · doi:10.1177/1753465816636557 · Cited by 126
Immune-Related Adverse Effects of Cancer Immunotherapy— Implications for Rheumatology
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · Rheumatic Disease Clinics of North America · doi:10.1016/j.rdc.2016.09.007 · Cited by 123
Toxicity management of immunotherapy for patients with metastatic melanoma
Linardou, H., & Gogas, H. J. (2016) · Annals of Translational Medicine · doi:10.21037/atm.2016.07.10 · Cited by 112
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2015) · Immunotherapy · doi:10.2217/imt.15.87 · Cited by 88
Abdel-Rahman, O. M., Elhalawani, H. M., & Fouad, M. (2015) · Expert Opinion on Drug Safety · doi:10.1517/14740338.2015.1085969 · Cited by 50
Abdel-Rahman, O., & Fouad, M. (2016) · Immunotherapy · doi:10.2217/imt-2015-0020 · Cited by 46
Cancer immunotherapy-induced rheumatic diseases emerge as new clinical entities
Cappelli, L. C., Shah, A. A., & Bingham, C. O. (2016) · RMD Open · doi:10.1136/rmdopen-2016-000321 · Cited by 43
Abdel-Rahman, O. M., Helbling, D., Schmidt, J., Petrausch, U., Giryes, A., Mehrabi, A., Schöb, O. M., Mannhart, M., Zidan, A., & Oweira, H. (2016) · Clinical Oncology · doi:10.1016/j.clon.2016.06.008 · Cited by 40
Komaki, Y., Komaki, F., Yamada, A., Micić, D., Ido, A., & Sakuraba, A. (2017) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.633 · Cited by 26
FRI0606 Characteristics and treatment of new onset arthritis after checkpoint inhibitor therapy
Christ, L., Mönch, S., Hasmann, S. E., Goldscheider, I., Heppt, M. V., Berking, C., Berger, F., Dechant, C., Skapenko, A., Schulze‐Koops, H., et al. (2017) · Annals of the Rheumatic Diseases · doi:10.1136/annrheumdis-2017-eular.6532 · Cited by 4
Cited by
Wang, Y., Zhou, S., Yang, F., Qi, X., Wang, X., Guan, X., Shen, C., Duma, N., Vera Aguilera, J., Chintakuntlawar, A., et al. (2019) · JAMA Oncology · doi:10.1001/jamaoncol.2019.0393 · Cited by 862
Loibl, S., Untch, M., Burchardi, N., Huober, J., Sinn, B. V., Blohmer, J.-U., Grischke, E.-M., Furlanetto, J., Tesch, H., Hanusch, C., et al. (2019) · Annals of Oncology · doi:10.1093/annonc/mdz158 · Cited by 695
The role of PD-1/PD-L1 and application of immune-checkpoint inhibitors in human cancers
Tang, Q., Chen, Y., Li, X., Long, S., Shi, Y., Yu, Y., Wu, W., Han, L., & Wang, S. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.964442 · Cited by 561
Efficacy of PD-1 or PD-L1 inhibitors and PD-L1 expression status in cancer: meta-analysis
Shen, X., & Zhao, B. (2018) · BMJ · doi:10.1136/bmj.k3529 · Cited by 559
Recent Advances in Hyperthermia Therapy‐Based Synergistic Immunotherapy
Chang, M., Hou, Z., Wang, M., Li, C., & Lin, J. (2021) · Advanced Materials · doi:10.1002/adma.202004788 · Cited by 450
Metadata
- Authors
- Baxi, S., Yang, A., Gennarelli, R. L., Khan, N., Wang, Z., Boyce, L., & Korenstein, D.
- Venue
- BMJ
- Publisher
- BMJ
- Published
- 2018-03-14
- Volume
- 360
- Pages
- k793
- ISSN
- 1756-1833 (ISSN-L)
- 0959-8138
- OpenAlex
- W2793180707
- Cited by
- 578
- References
- 48
- FWCI
- 9.30
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.